Clinical Trials Logo

Filter by:
NCT ID: NCT03915964 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

RA-BRIDGE
Start date: April 22, 2019
Phase: Phase 4
Study type: Interventional

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

NCT ID: NCT03912532 Recruiting - Clinical trials for NASH - Nonalcoholic Steatohepatitis

A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Start date: April 2019
Phase: Phase 2
Study type: Interventional

This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.

NCT ID: NCT03897257 Recruiting - Tinea Pedis Clinical Trials

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

Start date: March 15, 2019
Phase: Phase 2
Study type: Interventional

The study is being done to determine and compare the safety and effectiveness of an investigational combination therapy (low and high concentrations) versus mono-therapy (low and high concentrations) or mono-therapy (fixed concentration) in subjects with moccasin type tinea pedis.

NCT ID: NCT03891862 Recruiting - Clinical trials for Tardive Dyskinesia (TD)

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Start date: March 5, 2019
Phase: Phase 4
Study type: Interventional

This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.

NCT ID: NCT03882970 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

SURPASS-3
Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 59 weeks and may include up to 22 visits.

NCT ID: NCT03859869 Not yet recruiting - Clinical trials for Exocrine Pancreatic Insufficiency (EPI)

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Start date: June 28, 2019
Phase: Phase 4
Study type: Interventional

This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer that has been resected. This study will include resected participants who are post pancreatic cancer surgery, and an exploratory cohort in non-resected participants.

NCT ID: NCT03831191 Recruiting - Atopic Dermatitis Clinical Trials

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

ADmIRe
Start date: February 12, 2019
Phase: Phase 2
Study type: Interventional

The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).

NCT ID: NCT03830281 Recruiting - Clinical trials for Type 1 Diabetes Mellitus

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy

PRONTO-Pump-2
Start date: February 14, 2019
Phase: Phase 3
Study type: Interventional

The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).

NCT ID: NCT03823391 Recruiting - Clinical trials for Rheumatoid Arthritis (RA)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis

Start date: March 27, 2019
Phase: Phase 1
Study type: Interventional

This is a adalimumab active-controlled study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and efficacy following multiple intravenous (IV) injections of ABBV-3373 or multiple subcutaneous (SC) injections of adalimumab in participants with Rheumatoid Arthritis (RA) on background methotrexate (MTX).

NCT ID: NCT03807843 Not yet recruiting - Clinical trials for Chikungunya Virus Infection

Chikungunya Vaccine Study in Previously Exposed Adults

Start date: March 4, 2019
Phase: Phase 2
Study type: Interventional

Safety and immunogenicity of an investigational chikungunya vaccine will be tested in subjects with history of chikungunya infection. Initially 21 to 50 year old subjects will be enrolled; after favorable review of safety data, subjects aged 51 to 65 will be enrolled.